Ascletis announces promising results from a phase i study in australia for first-in-class muscle-preserving weight loss drug candidate asc47 for the treatment of obesity

Data from a phase i single ascending dose (sad) study in australia in subjects with elevated low-density lipoprotein cholesterol (ldl-c) showed that asc47, via subcutaneous (sq) injection ,  demonstrated a half-life of 21 days , supporting once-monthly administration in patients with obesity in multiple pre-clinical studies using the diet-induced obese (dio) mouse model, asc47 demonstrated healthy weight loss (muscle-preserving weight loss) compared to semaglutide in a head-to-head pre-clinical study using a dio mouse model, asc47 reduced total fat mass (-63.5%), statistically and significantly more than semaglutide (-39.6%). in the same study, asc47 statistically and significantly increased total muscle mass (+5.8%), while semaglutide decreased total muscle mass (-9.3%).
ASC Ratings Summary
ASC Quant Ranking